Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial
- 1 September 2006
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 368 (9540), 991-997
- https://doi.org/10.1016/s0140-6736(06)69294-5
Abstract
Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. By - Jiangtao Lin MD, Jiansan Zhang MSc, Xiaoping Dong PhD, Ha...Keywords
This publication has 15 references indexed in Scilit:
- Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trialThe Lancet, 2006
- Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) VaccineNew England Journal of Medicine, 2006
- Development and evaluation of influenza pandemic vaccinesThe Lancet Infectious Diseases, 2006
- Evolution of H5N1 Avian Influenza Viruses in AsiaEmerging Infectious Diseases, 2005
- Probable Person-to-Person Transmission of Avian Influenza A (H5N1)New England Journal of Medicine, 2005
- Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trialThe Lancet, 2003
- Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccinesMedical Microbiology and Immunology, 2002
- Selection of influenza vaccine strains and developing pandemic vaccinesVaccine, 2002
- Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenzaThe Lancet, 2001
- Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactionsJournal of Biological Standardization, 1979